Cannadorf

Company Overview

Snapshot

Founded in February 2019, Cannadorf operates with 1–10 employees. The company is developing a platform technology for the commercial production of premium plant extracts and specific Active Pharmaceutical Ingredients (APIs) from sterile plant tissue cultivated in bioreactors.

Business overview

Cannadorf is focused on advancing cannabis extraction to produce medically safe cannabinoids, terpenes, and flavonoids. The company aims to supply pharmaceutical companies with high-quality, sterile extracts and APIs, avoiding synthetic molecules. Its core technology involves cultivating sterile plant tissue in bioreactors for commercial production, targeting the pharmaceuticals, nutraceuticals, and cosmeceuticals markets within the Health Tech & Life Sciences sector.

Company Intelligence Q&A

What is Cannadorf's primary focus?

Cannadorf is dedicated to revolutionizing cannabis extraction to prioritize the production of medically safe cannabinoids, terpenes, and flavonoids for pharmaceutical, nutraceutical, and cosmeceutical applications.

What is Cannadorf's core technology?

Cannadorf is developing a platform technology that involves cultivating sterile plant tissue in bioreactors for the commercial production of premium plant extracts or specific Active Pharmaceutical Ingredients (APIs).

Which markets does Cannadorf aim to serve?

Cannadorf aims to meet the diverse needs of the pharmaceuticals, nutraceuticals, and cosmeceuticals markets by supplying high-quality and sterile extracts or APIs.

What is Cannadorf's vision for medical cannabis?

Cannadorf envisions a future where medical-based cannabis drugs are consistently safe and reliable, contributing to this by providing pharmaceutical companies with non-synthetic, high-quality extracts.

When was Cannadorf founded?

Cannadorf was founded in February 2019.